Pulmonary hypertension represents an important cause of morbidity and mortality in patients with mitral stenosis who undergo cardiac surgery, especially in the postoperative period. The aim of this study was to test the hypothesis that inhaled nitric oxide (iNO) would improve the hemodynamic effects and short-term clinical outcomes of patients with mitral stenosis and severe pulmonary hypertension who undergo cardiac surgery in a randomized, controlled study. Twenty-nine patients (4 men, 25 women; mean age 46 ؎ 2 years) were randomly allocated to receive iNO (n ‫؍‬ 14) or oxygen (n ‫؍‬ 15) for 48 hours immediately after surgery. Hemodynamic data, the use of vasoactive drugs, duration of stay, and short-term complications were assessed. No differences in baseline characteristics were observed between the groups. After 24 and 48 hours, patients receiving iNO had a significantly greater increase in cardiac index compared to patients receiving oxygen (p <0.0001). Pulmonary vascular resistance was also more significantly reduced in patients receiving iNO versus oxygen (؊117 dyne/s/cm 5 , 95% confidence interval ؊34 to ؊200, It has been shown that the pulmonary vasoconstriction present in clinical pulmonary hypertension can be alleviated in the short term using inhaled nitric oxide (iNO) through a mechanism involving vascular smooth muscle relaxation.
It has been shown that the pulmonary vasoconstriction present in clinical pulmonary hypertension can be alleviated in the short term using inhaled nitric oxide (iNO) through a mechanism involving vascular smooth muscle relaxation. 1 In humans, the ability of iNO to reduce pulmonary vascular resistance (PVR) while sparing systemic resistance by selective pulmonary vasodilatation has been exploited in patients with right ventricular dysfunction, 2, 3 acute lung injury, 4 and lung transplantation. 5 Specifically in patients with mitral stenosis, in whom chronic left-sided underfilling is prominent, the use of iNO has not been studied thoroughly. Most studies were not randomized or controlled, did not look specifically at clinical outcomes but only focused on the immediate hemodynamic effects of iNO, 6 used iNO during brief periods only, 7, 8 or were restricted to children 9 or women. 10 Fattouch et al 11 compared the use of iNO in mitral stenosis with inhaled prostacyclin and intravenous nitroprusside but did not include a control group not using vasodilators. This is the first randomized controlled study of patients with severe mitral stenosis and pulmonary hypertension using iNO compared to a control group receiving only oxygen. We observed not only the hemodynamic effects of each treatment but also the associated short-term clinical outcomes in these patients.
Methods
The study was approved by the institutional research committee, and all subjects gave written informed consent. Patients were consecutively selected at an outpatient cardiac valve disease clinic of a tertiary cardiology referral hospital. Men and women aged Ն18 years were selected if they met all the following inclusion criteria: mitral stenosis with a valve area Ͻ1.5 cm 2 ; severe pulmonary hypertension, defined as pulmonary artery systolic pressure (PASP) Ͼ60 mm Hg; and symptomatic disease with New York Heart Association functional class ՆII. Patients were excluded if they presented with concomitant valvular disease other than mitral stenosis (specifically moderate or important mitral regurgitation as defined by preoperative quantitative echocardiography) or had severe left or right ventricular dysfunction, defined as an ejection fraction Ͻ40% by preoperative echocardiography. Nineteen screened patients were excluded before randomization because of concomitant mitral regurgitation (15 patients) or severe left ventricular dysfunction (3 patients). Central computerized randomization of the treatment assignments was performed. Concealment was interrupted only when the patient was weaned from cardiopulmonary bypass and started to receive the designated therapy.
Before surgery, baseline 2-dimensional echocardiography and Doppler echocardiography were performed using commercially available equipment (Sonos 5500; Philips Medical Systems, Andover, Massachusetts). The ejection fraction, transmitral valve gradient, valve area calculated using the pressure half-time method, mitral valve echocardiographic score, 12 and PASP estimated using the modified Bernoulli equation were determined.
Before anesthesia induction in the operating room, a pulmonary artery catheter was placed in the right internal jugular vein or right subclavian vein, and pulmonary capillary wedge pressure, PASP, cardiac output calculated by thermodilution, and PVR were established. Cardiac output measurements were obtained from the mean of 3 consecutive end-expiratory readings. Patients were operated on using standard surgical procedures, and the choice of valve repair or replacement was left to the surgeons' discretion.
Immediately before weaning off cardiopulmonary bypass, patients randomized to the iNO arm had the NO delivery equipment attached to the anesthesia breathing circuit. The surgical team was not aware of the patient randomization allocation until this moment. Inhaled NO was delivered using NO tanks connected to the inspiratory limb of the airflow tubes at a concentration of 10 ppm, a dose with the best cost/benefit ratio according to previous dosing studies. 13 Concentrations of iNO and NO 2 were measured continuously with a dedicated monitoring device (NOxBox; Bedfont Instruments, Rochester, United Kingdom). Patients randomized to the oxygen control group continued to receive standard anesthesia care to maintain oxygen saturation Ͼ95%.
All patients were then transferred to a surgical intensive care unit (ICU) and continued the assigned treatment for up to 48 hours, in the ICU or in the ward. The criteria for ICU discharge were prespecified as hemodynamic stability (defined by a mean systemic arterial pressure Ͼ65 mm Hg), mechanical ventilation weaning with no signs of respiratory distress (as evaluated by the attending physician, who was blind to the outcomes of the study), urinary output Ͼ0.5 ml/kg/hour, and no significant bleeding from surgical sites. No patient was held in the ICU because of the protocol if he or she was considered apt for discharge and achieved the mentioned criteria. After extubation, patients received iNO or oxygen through a facial mask, keeping the aforementioned parameters. In all patients, an airtight sealed nonrebreathing cushioned face mask was used, allowing minimum leakage of either iNO or oxygen. Inhaled NO concentration was measured through a sampling line adjacent to the mask to guarantee a precise reading of the delivered concentration.
The use of any vasoactive drugs was permitted throughout the study and was left to the choice of the attending physician in the ICU, blinded to the outcomes of the study. At 24 and 48 hours after the initiation of iNO or control oxygen, a new reading of the pulmonary artery catheter was carried out, with the determination of the same parameters obtained before surgery. After 48 hours, patients withdrew oxygen therapy unless contraindicated by the assisting physician. Patients receiving iNO were progressively weaned, with total switch to room air or oxygen by mask as needed in 1 hour. All patients were followed during the total hospital stay for the assessment of predefined complications (acute renal insufficiency, infections, need for reintubation, liver failure, and death).
The primary outcomes of this study were the differences at 48 hours compared to the baseline cardiac index and PVR in each treatment group. These primary end points were chosen to allow a more accurate sample size calculation as well as to provide a more relevant link to the clinical effects. Secondary outcomes included clinical variables regarding postoperative complications, total days in the ICU, total hospital stay, and number and dosing of systemic intravenous vasoactive drugs. Complications were defined as acute renal insufficiency (renal output Ͻ0.3 ml/kg/hour), need for reintubation, sepsis according to standardized definitions, 14 cardiogenic shock, and need for urgent reoperation.
Data are presented as mean Ϯ SD, except for total hospital and ICU length of stay, which were not normally distributed and are presented as median and interquartile range. Comparisons among absolute values of the hemodynamic parameters preoperatively and at 24 and 48 hours Figure 1 . Values of pulmonary capillary wedge pressure, PASP, cardiac index, and PVR in patients using iNO (black circles) versus oxygen (black squares) preoperatively and at 24 and 48 hours after surgery. There was a significant decrease in PVR at 48 hours in patients using iNO compared to oxygen.
* p Ͻ 0.005. Figure 2 . Changes compared to baseline of hemodynamic data in patients using oxygen (white bars) and iNO (black bars). Cardiac index increased much more significantly in patients receiving iNO at 24 and 48 hours (p Ͻ0.01 for both) compared to preoperative values.
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The American Journal of Cardiology (www.ajconline.org) were done using analysis of variance for repeated measures on ranks with Tukey's and profile tests for time and group differences. Analyses of the differences as well as other comparisons regarding the iNO and control groups were made using unpaired Student's t tests for continuous variables, Mann-Whitney or chi-square tests for proportions, and Fisher's exact tests as needed. Sample size was calculated on the basis of an ␣ error of 0.05 and power of 80% to detect a 40% difference in PVR between the 2 groups. We calculated the number of subjects needed for the study to be 30 (15 in each group) on the basis of previous studies. 10 All calculations were done using intention-to-treat analysis and were performed in SAS version 9.1.3 (SAS Institute Inc., Cary, North Carolina). Significance was assumed at a 2-tailed p value Ͻ0.05.
Results
Twenty-nine patients (86% women, mean age 46 Ϯ 2 years) were enrolled in the study, with a total evaluation of 48 patients. One patient withdrew consent on the morning of the surgery and was not included in the final analysis. The baseline clinical characteristics of the 2 groups are listed in Table 1 . No significant differences between the groups were observed. Patients enrolled were characterized by significant mitral stenosis (mean valve area 0.89 Ϯ 0.04 cm 2 ) with severe pulmonary hypertension (mean PASP 73 Ϯ 3 mm Hg, mean PVR 303 Ϯ 31 dyne/s/cm 5 ). Only 1 death occurred; a patient in the oxygen group died 22 days after surgery with sepsis and multiple-organ failure. All randomized patients received the assigned treatment with iNO or oxygen during the full duration of the planned intervention, with no crossovers. Patients in the iNO group were mechanically ventilated for 7.5 Ϯ 8.5 hours, while patients receiving oxygen were ventilated for 15.1 Ϯ 21.8 hours (p ϭ 0.23). No patient developed significant mitral valve regurgitation as assessed by echocardiography 7 days after surgery (data not shown).
Changes in hemodynamic parameters after surgery are presented in Figures 1 and 2 . After 24 and 48 hours, the 2 groups had significant reductions in pulmonary capillary wedge pressure, with no differences between patients receiving iNO or oxygen. Significant decreases also occurred in PASP at 24 and 48 hours compared to that at baseline in the 2 groups, with no differences between them. However, the cardiac index increased significantly in patients receiving iNO at 24 and 48 hours (p Ͻ0.0001 for both). Moreover, although the cardiac index increased significantly compared to that at baseline in the 2 groups after 24 hours, this increase was sustained at 48 hours only in patients who received iNO, with a mean increase of 1. Patients who received iNO had significantly shorter ICU stays compared to patients who received oxygen (Table 1) . However, total hospital stay was similar in the 2 groups (median 10 days, interquartile range 6.0 in iNO group vs median 13 days, interquartile range 16.25 in the oxygen group, p ϭ 0.14).
The use of concurrent vasoactive drugs might have interfered with the results regarding the previous hemodynamic measurements. Table 2 lists systemic intravenous vasoactive drugs used in the 2 groups during ICU and hospital stay. Although no significant differences were observed regarding the percentage of patients using each drug or the maximum dose used in each patient, the mean number of systemic vasoactive drugs used during hospital stay was significantly smaller in the iNO group (2.1 Ϯ 0.14) compared to that in patients receiving only oxygen (2.6 Ϯ 0.16) (p ϭ 0.046). There were a nonsignificant smaller proportion of patients receiving nitroprusside and milrinone in the iNO group compared to controls. Other drugs known to significantly affect pulmonary pressure were not used by any patient in our study either during ICU or ward stay.
The percentage of patients with any of the predefined complications was similar in the 2 groups (9 of 15 [60%] in the oxygen group vs 4 of 14 [29%] in the iNO group, p ϭ 0.14). According to the definitions of complications previously mentioned, 3 patients in the iNO group needed urgent reoperation due to bleeding complications (1 for cardiac tamponade and 2 for Ͼ500 ml of sanguineous drainage in the first hour postoperatively), and 1 patient developed sepsis. In the oxygen group, 2 patients needed reintubation, 2 patients underwent urgent reoperation (1 for cardiac tam- 
Discussion
We have demonstrated that treatment with iNO immediately after surgery in patients with significant mitral stenosis and severe pulmonary hypertension is associated with increased cardiac output and reduced PVR. This in turn translated into shorter ICU stays and less need for systemic vasoactive drug use.
Different therapies for the postoperative management of pulmonary hypertension are available and include intravenous nitroprusside, inhaled prostacyclin, and intravenous phosphodiesterase inhibitors. 15 In contrast with these therapies, iNO is rapidly inactivated through a hemoglobinmediated process while still in the pulmonary circulation, 16 with clinical studies showing no effect on systemic circulation 17, 18 and an established safety profile even up to 40 ppm. 19 In our patients, also not statistically significant, there was a smaller proportion of patients in the iNO group receiving nitroprusside as well as milrinone, and no differences were found in the use of other systemic vasoactive drugs. This reinforces the benefits of iNO use, because these patients exhibited a significant decrease in PVR while using, at most, the same doses of vasoactive drugs.
In our study, we chose to use a dose of 10 ppm of iNO to further minimize any toxic risks associated with the drug and due to previous dose-response studies showing no benefits of increased doses. 13 The 34% reduction in PVR seen in patients using iNO is in accordance with previous reports indicating reductions of PVR up to 27% to 45% with iNO, with more significant reductions being obtained with 20 than at 10 ppm. 7, 8, 20 We also observed an increase in cardiac output after surgery in the 2 groups, but the increase with iNO was significantly greater and sustained. This finding has also been reported by others but was not reproduced in all iNO studies. 10, 21 This apparent discrepancy can be attributed to differences in preoperative cardiac function or hemodynamic conditions, all of which might influence the final cardiac output observed with the treatment. In fact, in the presence of ventricular dysfunction, an increase in left atrial end-diastolic pressure with increased pulmonary blood flow with iNO may lead to pulmonary edema and reduced cardiac output. 22 It is also interesting to point out that despite the reductions in pulmonary hypertension observed in the study, the values of the mean PASP were still elevated in the 2 groups. Part of this is due to the vast and complex pathophysiology of pulmonary hypertension, in which a variety of arterial abnormalities play a role at different stages in the same patient. 23 Therefore, acute interventions in the postoperative setting may revert only part of the functional and structural changes represented by intimal hyperplasia, medial hypertrophy, adventitial proliferation, thrombosis, and inflammation. The increase in cardiac output and reduced PVR observed in the iNO group in this study was associated with an improvement in several clinical parameters that may result in improved management of these patients after surgery. First, the total ICU stay was reduced using iNO, a finding also reported by others recently. 11 We also found that the use of iNO permitted a more judicious use of systemic vasoactive drugs, with a better hemodynamic profile in these patients despite the use of a reduced number of these agents. Interestingly, a trend was noted toward fewer complications in patients receiving iNO compared to controls, with a shorter total hospital stay. Patients with no complications had significantly higher reductions in PVR postoperatively than did patients presenting with any complications. This may reflect the baseline reversibility of pulmonary hypertension in these patients, but the role of iNO in this reduction cannot be disregarded. Moreover, patients enrolled in this study represented a very high risk population, with a mean PASP of 73 Ϯ 3 mm Hg, much higher than the 39 to 61 mm Hg reported in other studies. 7, 8, 24, 25 Therefore, any degree of reduction in PVR that would mitigate complications in these patients would be desirable.
Limitations of this study include the hemodynamic readings at 24 and 48 hours in the ICU setting, while the patients were taking other vasoactive drugs that might have confounded our results, although no significant differences were observed in terms of frequency and maximum doses of these drugs in the 2 groups. The use of right ventricular parameters as outcomes of the study would also have enhanced our results, but we believe that other variables studied already give independent and prognostic information regarding the right-sided cardiac chambers to allow the conclusions presented here. Last, although it could be desirable to blind the effective treatment, because we needed to monitor the values of NO 2 for safety reasons, this approach would not seem possible.
